scholarly journals Total artificial heart implantation in a young Marfan syndrome patient

2018 ◽  
Vol 41 (3) ◽  
pp. 175-177 ◽  
Author(s):  
Prashant Rao ◽  
Jack B Keenan ◽  
Taufiek K Rajab ◽  
Samuel Kim ◽  
Richard Smith ◽  
...  

Introduction: Cardiovascular complications represent the leading cause of morbidity and mortality in patients with Marfan syndrome. Here, we describe a unique case where a total artificial heart was implanted in a young Marfan syndrome woman. Methods: A 22-year-old postpartum African American female with Marfan syndrome developed multiple severe valve dysfunction and biventricular failure that was refractory to medical management. She previously had a Bentall procedure for Type A aortic dissection and repair of a Type B dissection. Results: We implanted a total artificial heart with a good outcome. Conclusion: Total artificial heart is a durable option for severe biventricular failure and multiple valvular dysfunction as a bridge to transplant in a young patient with Marfan syndrome.

2020 ◽  
Vol 58 (6) ◽  
pp. 1175-1181
Author(s):  
Charles-Henri David ◽  
Philippe Lacoste ◽  
Prakash Nanjaiah ◽  
Philippe Bizouarn ◽  
Thierry Lepoivre ◽  
...  

Abstract OBJECTIVES At our centre, the SynCardia temporary Total Artificial Heart (TAH-t) (SynCardia Systems, LLC, Tucson, AZ, USA) is used to provide long-term support for patients with biventricular failure as a bridge to a transplant. However, a heart transplant (HT) after such support remains challenging. The aim of this retrospective study was to assess the immediate and long-term results following an HT in the cohort of patients who had a TAH-t implant. METHODS A total of 73 patients were implanted with the TAH-t between 1988 and 2019 in our centre. Of these 73 consecutive patients, 50 (68%) received an HT and are included in this retrospective analysis of prospectively collected data. RESULTS In the selected cohort, in-hospital mortality after an HT was 10% (n = 5). The median intensive care unit stay was 33 days (range 5–278). The median hospital stay was 41 days (range 28–650). A partial or total pericardiectomy was performed during the HT procedure in 21 patients (42%) due to a severe pericardial reaction. Long-term survival rates after an HT at 5, 10 and 12 years were 79.1 ± 5.9% (n = 32), 76.5 ± 6.3% (n = 22) and 72.4 ± 7.1% (n = 12), respectively, which was similar to the long-term survival for a primary HT without TAH-t during the same period (n = 686). An HT performed within 3–6 months post-TAH-t implantation appeared to provide the best survival (P = 0.007). Eight (16%) patients required chronic dialysis during the subsequent follow-up period, with 3 patients requiring a kidney transplant. CONCLUSIONS The long-term outcomes with the SynCardia TAH-t as a bridge to transplant in patients with severe biventricular failure are very encouraging. Our review noted that an HT following TAH-t can be technically challenging, especially in the case of a severe pericardial reaction, with potential pitfalls that should be recognized preoperatively.


2021 ◽  
Vol 40 (4) ◽  
pp. S528
Author(s):  
G.T. Gibson ◽  
S. Rangasamy ◽  
J. Contreras ◽  
A. Singhvi ◽  
A. Fox ◽  
...  

2012 ◽  
Vol 31 (4) ◽  
pp. S109-S110
Author(s):  
A. Nguyen ◽  
M. Pozzi ◽  
C. Mastroianni ◽  
P. Leprince ◽  
P. Alain ◽  
...  

1991 ◽  
Vol 2 (3) ◽  
pp. 587-597
Author(s):  
Lawrence E. Barker

In the early 1800s, an awareness of potential ventricular failure stimulated interest in artificial heart replacement. In 1937 the first total artificial heart (TAH) was implanted into the chest of a dog by Russian physicians. The primary driving force for mechanical cardiac assistance developed from the necessity for circulatory assistance in order to perform corrective cardiac surgery. In 1953 the first successful closure of an atrial septal defect using extracorporeal circulation was performed. During the following decade the concept of using mechanical devices to assist the failing heart was aggressively pursued. This culminated in the first implant of a TAH in a human in 1969 as a bridge to transplant. Clinical implant of the TAH as a permanent device was performed in 1982 by researchers at the University of Utah. This patient lived for 112 days. Three successive permanent implants were performed in Louisville, Kentucky, with one patient surviving for 620 days. All of these permanent TAH patients suffered from device-related complications including bleeding, infection, and thromboembolic events. It became apparent that the present configuration of the TAH with its external drive lines and large air console was not ideal for long-term support. In 1985 the first implant of the Symbion J-7-100 TAH (Jarvik-7) as a bridge to transplant was performed. This patient was supported by the device for 9 days and was successfully transplanted and discharged home. Since 1985 more than 170 patients have been bridged using the Symbion J-7 TAH with more than 70% of these patients being successfully transplanted. The incidence of thromboembolic events has dramatically reduced with better understanding of anticoagulation requirements. Infection continues to be the greatest potential complication with these patients. In spite of this, the pneumatic TAH has proved to be an adequate bridge to transplant device


1998 ◽  
pp. 421-423
Author(s):  
Ricardo J. Moreno-Cabral ◽  
Robert M. Adamson ◽  
Walter P. Dembitsky ◽  
Pat O. Daily ◽  
Francisco A. Arabía ◽  
...  

2017 ◽  
Vol 20 (3) ◽  
pp. 266-269 ◽  
Author(s):  
Masashi Kawabori ◽  
Chitaru Kurihara ◽  
Yair Miller ◽  
Kent A. Heck ◽  
Roberta C. Bogaev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document